HC Wainwright Lifts Earnings Estimates for Solid Biosciences

Solid Biosciences Inc. (NASDAQ:SLDB) – HC Wainwright boosted their FY2026 EPS estimates for shares of Solid Biosciences in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($1.60) for the year, up from their previous estimate of ($1.63). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.56) EPS.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.05.

Several other equities research analysts have also issued reports on the company. William Blair started coverage on Solid Biosciences in a research note on Monday. They set an “outperform” rating for the company. Truist Financial increased their price objective on Solid Biosciences from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, August 21st. UBS Group assumed coverage on Solid Biosciences in a research report on Wednesday, October 14th. They set a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, October 15th. Finally, Royal Bank Of Canada started coverage on Solid Biosciences in a research report on Wednesday, September 16th. They issued an “outperform” rating and a $18.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Solid Biosciences Stock Up 6.5%

SLDB opened at $7.02 on Monday. The stock has a market cap of $752.68 million, a PE ratio of -3.92 and a beta of 2.65. Solid Biosciences has a 52 week low of $4.01 and a 52 week high of $11.45. The business’s fifty day simple moving average is $7.43 and its 200 day simple moving average is $7.67.

Institutional Trading of Solid Biosciences

A number of institutional investors have recently made changes to their positions in SLDB. Perceptive Advisors LLC grew its holdings in shares of Solid Biosciences by 0.6% in the first quarter. Perceptive Advisors LLC now owns 11,906,646 shares of the company’s stock worth $85,728,000 after purchasing an additional 73,107 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Solid Biosciences during the 1st quarter valued at $28,877,000. Redmile Group LLC boosted its position in Solid Biosciences by 8.1% during the 1st quarter. Redmile Group LLC now owns 2,011,895 shares of the company’s stock valued at $14,486,000 after buying an additional 151,353 shares during the period. Monashee Investment Management LLC boosted its position in Solid Biosciences by 5.2% during the 1st quarter. Monashee Investment Management LLC now owns 1,420,295 shares of the company’s stock valued at $10,226,000 after buying an additional 70,524 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Solid Biosciences by 40.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 956,135 shares of the company’s stock valued at $6,877,000 after buying an additional 277,051 shares during the period. Hedge funds and other institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc (NASDAQ: SLDB) is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.

Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.